---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-040303"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:01:55.713121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocuphire licenses Nyxol to FamyGen/Viatris for $35M upfront plus milestones and royalties

## Summary
- Ocuphire receives $35M upfront; FamyGen funds Nyxol development through FDA approvals.
- Up to $130M in milestones; first $10M on FDA approval for mydriasis reversal expected in 2023.
- Tiered double-digit royalties on worldwide net sales through 2040.
- Viatris to commercialize Nyxol globally; Ocuphire retains rights outside licensed territory.
- Cash position extended into 2025, supporting presbyopia/NVD trials and APX3330 retina program.

## SEC filing metadata
- accession: 0001140361-22-040303
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036122040303/0001140361-22-040303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036122040303/brhc10043812_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-040303
- JSON: https://secwatch.observer/filing/0001140361-22-040303.json
- Plain text: https://secwatch.observer/filing/0001140361-22-040303.txt

## Key facts
- Material Agreements
  Opus Genetics, Inc. entered into License and Collaboration Agreement with FamyGen Life Sciences, Inc. valued at upfront cash payment of $35 million; potential additional payments of up to $130 million in the aggr (effective 2022-11-06).
  - Action: entry
  - Agreement: license
  - Counterparty: FamyGen Life Sciences, Inc.
  - Value: upfront cash payment of $35 million; potential additional payments of up to $130 million in the aggr
  - Effective: 2022-11-06
  source text: On November 6, 2022, Ocuphire Pharma, Inc. (“ Ocuphire ”) entered into a License and Collaboration Agreement (the “ License Agreement ”) with FamyGen Life Sciences, Inc. (“ Famy ”), pursuant to which Ocuphire granted Famy an exclusive, perpetual, sub-licensable license to develop, manufacture, import, export and commercialize (i) Nyxol for treating (a) reversal of mydriasis, (b) night vision disturbances or dim light vision, and (c) presbyopia, and (ii) Nyxol and low dose pilocarpine for treating presbyopia (together, the “ Products ”) worldwide except for certain countries and jurisdictions in Asia (the “ Territory ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036122040303/0001140361-22-040303-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.